Primer: Dechra Pharmaceuticals (DPH LN) - Aug 2026
Following its acquisition by private equity firm EQT for £4.5 billion in early 2024, Dechra is in a transitional phase, focusing on long-term...
102 Views
𝛼SK or SearchENTITY
Dechra Pharmaceuticals (DPH LN)
Dechra Pharmaceuticals (DPH LN)
44
Analysis
Health Care • United Kingdom
Dechra Pharmaceuticals is a global specialist in the development, manufacture, and marketing of high-quality veterinary pharmaceuticals and related products, focusing on companion animals, equine, and food-producing animals. Key products include treatments for endocrinology, dermatology, and pain management, such as Vetoryl for Cushing's disease in dogs and Felimazole for hyperthyroidism in cats. The company was founded in 1997 and moved its global headquarters to Boston, Massachusetts, in June 2026.
morex